DexCom (DXCM -6%) slips on modestly higher volume in apparent reaction to continuous glucose monitoring (CGM) competitor Abbott’s announced partnership with insulin pump seller Tandem Diabetes Care aimed at developing and commercializing integrated solutions with the former’s FreeStyle Libre sensor-based CGM device.
Investors appear to perceive a potential competitive threat to DexCom’s G6 CGM system.
https://seekingalpha.com/news/3505797-dexcom-6-percent-abbott-tandem-deal
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.